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Background. Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related mortality; nevertheless, there are few
data regarding detection of circulating tumor cells (CTCs) in NSCLC, compared to other kinds of cancers in which their prognostic
roles have already been defined. This difference is likely due to detection methods based on the epithelial marker expression which
ignore CTCs undergoing epithelial-mesenchymal transition (CTCsEMT). Methods. After optimization of the test with spiking
experiments of A549 cells undergoing TGF-β1-induced EMT (A549EMT), the CTCsEMT were enriched by immunomagnetic
depletion of leukocytes and then characterized by a RT-PCR assay based on the retrieval of epithelial and EMT-related genes.
Blood samples from ten metastatic NSCLC patients before starting treatment and during chemotherapy were used to test this
approach by longitudinal monitoring. Ten age- and sex-matched healthy subjects were also enrolled as controls. Results.
Recovery experiments of spiked A549EMT cells showed that the RT-PCR assay is a reliable method for detection of CTCsEMT.
CTCsEMT were detected in three patients at baseline and in six patients after four cycles of cysplatin-based chemotherapy.
Longitudinal monitoring of three patients showed that the CTCsEMT detection is related to poor therapeutic response.
Conclusions. The RT-PCR-based approach for the evaluation of CTCsEMT phenotype could be a promising and inexpensive tool
to predict the prognosis and the therapeutic response in NSCLC patients.
1. Introduction
The metastatic process consists in the reproduction at dis-
tance of tumor masses coming from the primary tumor cells,
with a notable spatial and distrectual discontinuity from the
initial localization. This process is subdivided into multiple
steps that are all necessary to form a new tumor colony: loss
of cell-to-cell adhesion, extracellular matrix invasion, intra-
vasation and spreading into the bloodstream, escape from
the circle, and secondary lesion establishment [1]. These
structural and functional changes in the cancer tissue take
place through a peculiar modulation of tumor cell phenotype
known as epithelial-mesenchymal transition (EMT), a pro-
cess characterized by a dramatic change of epithelial cells
that lose their differentiated phenotype to acquire ex novo
mesenchymal features [2]. EMT culminates with the acqui-
sition of cell motility and invasiveness by the reorganization
of the cytoskeleton dynamics such as the rearrangements of
the intercellular junctions and the changes in apical-basal
polarity [3].
The EMT program is sustained by hypoxia and cellular
stress [4] and/or turned on by many transcription factors
(TFs), including Snail, ZEB, and Twist. Working in tan-
dem with multiple signaling pathways such as TGF-β,
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Wnt, Notch, and NF-κB, their activity seems to upregulate
the expression of genes related to mesenchymal phenotype
(i.e., N-cadherin, fibronectin, and vimentin) and to sup-
press epithelial genes such as epithelial cell adhesion mol-
ecule (EpCAM), E-cadherin, β-γ-catenin, and cytokeratins
(CKs) [5, 6].
Subsequently to the EMT process, cancer cells that con-
stantly spread in the bloodstream are defined as circulating
tumor cells (CTCs) [7]. It is believed that only a little part
of CTCs consists of cells able to start a clonal metastatic
lesion; in fact, most of them are subject to phenomena of
immunomodulation and hemodynamic pressure that lead
to their destruction [7–9].
Considering that CTCs are extremely rare, their identifi-
cation and characterization require the application of highly
sensitive and specific techniques. The pivotal technique for
in vitro diagnostic use (CellSearch® Veridex, Menarini Sili-
con Biosystems) is based on the principle of immunoaffinity
toward CTC surface antigens by immunomagnetic beads
coated with antibodies toward EpCAM. The CTC count is a
good marker for tumor growth and aggressiveness; it has
been shown that a higher CTC count is associated with a
decreased progression-free survival and overall survival of
patients under treatment for metastatic breast [10], colorectal
[11], or prostate cancer [12].
Non-small cell lung cancer (NSCLC) is the leading
cause of cancer death due to distant metastases involving
approximately 70% of patients who come to diagnosis
[13]. The detection of CTCs in advanced NSCLC is sur-
prisingly low with respect to other epithelial tumors [1].
In fact, the use of isolation strategies, exclusively based
on epithelial marker expression, led to a CTC detection
in only a third of metastatic patients [1, 14, 15] and in a
very low percentage of nonmetastatic subjects [16].
CTCs are heterogeneous and are often characterized by
downmodulation of epithelial markers; this feature makes
the standard approaches less effective and suggests the need
of an alternative detection method [17].
In this clinical setting, considering that EpCAM-based
methods have low sensitivity, selection bias, and poor spec-
ificity [18], other Non-EpCAM-based capture methods
have been proposed to improve CTC detection in NSCLC
[19–21]; some of these are based on a negative enrichment
by immunomagnetic depletion of leukocytes [22]. To mini-
mize the leucocyte noise, density-based techniques (i.e.,
Ficoll-Hypaque or OncoQuick) could be used for the
enrichment step before detection [23]. Then, the negative
enrichment allows the recovery of the CTCsEMT that can
be highlighted using several techniques for the detection
of EMT-related elements [24–27].
In the present study, we designed a RT-PCR approach
to improve the detection of CTCsEMT in metastatic
NSCLC patients. To this purpose, we analyzed the periph-
eral blood sample for the expression of epithelial (CEA-
CK19) and EMT-related genes such as vimentin and
EMT transcription factors (Snail1-2, ZEB1-2, and Twist1-2).
We optimized our method on A549 cells undergoing
TGF-β1-induced EMT spiked into blood samples of healthy
donors at serial dilution. This approach was subsequently
tested on blood samples of ten metastatic NSCLC patients
before starting treatment and during chemotherapy by a
longitudinal monitoring. Ten healthy subjects, age and
sex matched, were recruited in the control arm as nega-
tive controls.
Based on molecular marker expression, we identified
patients with CTCs with epithelial phenotype and/or biphe-
notypic CTCs with expression of EMT-related genes. After
defining the CTC molecular profile before treatment (T0,
baseline), we analyzed whether chemotherapy induces
dynamic changes and if those could be related to a response
to treatment. For this purpose, we monitored the patients at
the time of first posttreatment CT scans (T1) and for still
living patients at the time of second posttreatment CT
scans (T2).
According to our thresholds and parameters, we detected
CTCsEMT in three patients at baseline and in six patients after
4 cycles of cysplatin-based chemotherapy. By longitudinal
monitoring, we found a poor therapeutic response in patients
with CTCsEMT positivity.
This exploratory study, although limited to a very small
number of patients, suggests that the RT-PCR-based
approach for CTCsEMT detection could be a promising tool
useful to predict the prognosis and the therapeutic response
also in NSCLC patients.
2. Materials and Methods
2.1. Optimization of Method for Epithelial-Mesenchymal
Transitioned Cell (A549EMT) Isolation and Characterization
2.1.1. Cell Cultures and Treatments to Induce In Vitro EMT
Phenotype. The A549 (human lung adenocarcinoma) cell line
[28] was cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and antibiotics. EMT was induced by 5ng/ml of TGF-β1
(PeproTech Inc., Rocky Hill, NY, USA) for 48 hours [29],
and the induction of A549EMT phenotype was evaluated by
morphological and immunofluorescence analyses. Regarding
morphological analysis, the cell cultures were studied with an
Axiovert 200 inverted microscope (Zeiss, Oberkochen,
Germany) equipped with differential interference contrast
(DIC) optics and with Axiovision Image Analysis System
(Zeiss). For the immunofluorescence analysis, the A549 cells
were fixed with 4% paraformaldehyde followed by treatment
with 0.1M glycine for 20min at 25°C and with 0.1% Triton
X-100 for additional 5min at 25° for cell membrane perme-
abilization. Cells were then incubated with the following
primary antibodies: anti-CD326/EpCAM-PE mAb (1 : 10 in
PBS; Miltenyi Biotec, Bergisch Gladbach, Germany) and
anti-vimentin mAb (1 : 50 in PBS; clone V9; Dako, Glostrup,
Denmark) for 15min. The unconjugated primary antibody
was visualized, after appropriate washing with PBS, by using
goat anti-mouse IgG–FITC (1 : 50 in PBS; Cappel Research
Products, Santa Ana, CA, USA) for 30min at 25°C. Nuclei
were stained with 4,6-diamidino-2-phenylindole dihy-
drochloride (DAPI, 1 : 10,000; Sigma Chemicals, St. Louis,
MO, USA). Fluorescence signals were analyzed by ApoTome
System (Zeiss) connected with an Axiovert 200 Inverted
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Microscope (Zeiss), and image analysis was performed using
the Axiovision software (Zeiss).
2.1.2. Immuno-Magnetic A549EMT Isolation. To optimize the
isolation technique of CTCsEMT, we evaluated the recovery of
A549EMT cells diluted in a healthy volunteer’s blood samples.
We used a tenfold serial dilution (10→105/7.5mL) of cul-
tured cells in order to determine a recovery ratio and linearity
of the analysis method. In the preenrichment step, we iso-
lated the A549EMT cells using density gradient centrifugation
over Ficoll-Paque™ PLUS (Amersham Biosciences/GE
Healthcare, Uppsala, Sweden) recovering the PBMC layer
where our cultured cells are included for physical character-
istics of density. Then, the immunomagnetic negative selec-
tion helped us to clean the recovered sample from PBMC
noise and to keep our epithelial and/or transition cells. To
achieve this result, the PBMC was resuspended for magnetic
labeling in 80μL of MACS® separation buffer (Miltenyi Bio-
tec) and incubated for 30min at 4°C with 20μL of CD45
MicroBeads (Miltenyi Biotec). Then, LS separation columns
(Miltenyi Biotec) were equilibrated with 0.5ml of MACS
separation buffer, and the microbead-labeled cells were sub-
jected to a magnetic field through the column. Thus, the col-
umn was removed from the magnetic separator, and the
eluate was recovered. So we analyzed the eluate with quanti-
tative immunofluorescence (qIF), flow cytometry (FC), and
RT-PCR (Figure 1).
2.1.3. A549EMT Cell Count and Linearity Evaluation of the
Methods. To evaluate the recovery ratio and the linearity of
A549EMT isolation method, the spiked A549EMT cells were
counted by qIF analysis as previously described [30, 31].
After permeabilization, the samples were incubated with
anti-vimentin mAb (1 : 50 in PBS; clone V9; Dako) for 15
minutes and goat anti-mouse IgG–FITC (1 : 50 in PBS; Cap-
pel Research Products) for 30min and, after extensive wash-
ing, with anti-CD45-PE (1 : 10 in MACS Miltenyi Biotech
separation buffer) for 15min at 4°C. Cells were then washed
and centrifuged at 1300 rpm for 6min at 25°C, and the pellet
was resuspended in 10μL of cell solution and spotted on
8-well diagnostic slides (Menzel-Glaser, Braunschweig,
Germany), left to dry, and fixed with acetone for 8min at
−20°C. Nuclei were stained with DAPI (1 ng/mL, Sigma
Chemicals, St. Louis, MO, USA). The A549EMT were identi-
fied as vimentin+/CD45− cells, and the cell counts were
assessed independently by two pathologists.
As an additional control method of cell count, the sam-
ples of spiked A549EMT were analyzed in parallel with
MACSQuant Analyzer flow cytometer (Miltenyi Biotec
GmbH). The excitation and emission wavelengths were 488
and 525nm for anti-vimentin-FITC detection (B1 channel)
and 488 and 585nm for anti-CD45-PE detection (B2 chan-
nel). The fluorescence signals were analyzed by MACSQuan-
tify software (Miltenyi Biotec GmbH), and the cells with the
expression of vimentin were gated and counted.
To assess the linearity of control methods for cell count,
the number of recovered cells obtained by qIF and CF was
correlated by linear regression to the number of spiked
A549EMT cells. To verify the reliability of RT-PCR method,
the expression levels of all target genes were compared by
Bland & Altman plot to qIF and CF counts across all the data
points. To confirm the linearity of RT-PCR assay, the expres-
sion levels of target genes were correlated by linear regression
to the number of spiked A549EMT cells.
2.1.4. Primers. Oligonucleotide primers for target genes and
for the housekeeping gene (GAPDH) were chosen with the
assistance of the Oligo 5.0 computer program (National Bio-
sciences, Plymouth, MN, USA) and purchased from Invitro-
gen (Carlsbad, CA, USA). The primers used are shown in
Table 1. For each primer pair, we performed no-template
control and no-reverse-transcriptase control (RT negative)
assays, which produced negligible signals.
TGF-훽1 treatment
for induction of
in vitro EMT phenotype
A549 cells
Spiking of A549EMT
in normal blood samples
Preenrichment step with
Ficoll-Paque
Immunolabeling
with 훼-CD45 microbeads
Immunomagnetic
selection of CD45 cells
Quantitative
immunofluorescence
Cytofluorimetry
RT-PCR assay
Recovery
of A549EMT
Figure 1: Schematic drawing of the immunomagnetic isolation and detection of A549EMT cells. After negative enrichment by
immunomagnetic depletion of leukocytes, putative A459EMT cells spiked in the normal blood samples were analyzed with quantitative
immunofluorescence microscopy, cytofluorimetry, and RT-PCR assay.
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2.1.5. RNA Extraction and cDNA Synthesis. RNA was
extracted using the TRIzol method (Invitrogen) according
to the manufacturer’s instructions and eluted with 0.1%
diethylpyrocarbonate- (DEPC-) treated water. Total RNA
concentration was quantitated by spectrophotometry, and
the quality was assessed by measuring the optical density
ratio at 260/280 nm. RNA samples were stored at −80°C.
After denaturation in DEPC-treated water at 70°C for
10min, 1μg of total RNA was used to reverse transcription
using iScript™ cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA) according to the manufacturer’s instructions.
2.1.6. PCR Amplification and Real-Time Quantitation. RT-
PCR was performed using the iCycler Real-Time Detection
System (iQ5 Bio-Rad) with optimized PCR conditions. The
reaction was carried out in 96-well plate using iQ SYBR
Green Supermix (Bio-Rad) adding forward and reverse
primers for each gene and 1μl of diluted template cDNA to
a final reaction volume of 15μL. All assays included a nega-
tive control, and they were replicated three times. Real-time
quantitation was performed with the help of the iCycler IQ
optical system software version 3.0a (Bio-Rad Laboratories),
according to the manufacturer’s manual. Results are reported
as mean± standard error (SE) from three different experi-
ments in triplicate. For CEA and CK19 gene expression, the
external standard was prepared as previously described
[31]. To perform external standards for target genes of
vimentin and EMT trascription factors (EMT-TF), tenfold
serial dilutions of cDNA from A549EMT cell line was used
(10→106 A549EMT cells). For RT-PCR data analysis, the tar-
get gene expression values were corrected with housekeeping
gene expression values, to target genes/GAPDH mRNA
ratios. Due to background transcription in the PBMC, the
cutoff levels of target genes were defined using receiver-
operator characteristic (ROC) curves based on the analysis
(GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego, CA, USA) of PBMC samples (true neg-
atives) and samples of cell lines used to perform the target
gene external standards (true positives).
2.2. Detection of CTCsEMT in NSCLC Patients
2.2.1. Ethic Statement, Patients, and Blood Sample Collection.
Patients and healthy volunteers provided their written
informed consent to participate in this study, according to a
protocol study approved by the Ethical Committee of
Sant’Andrea University Hospital (number 97/2012). Ten
consecutive NSCLC metastatic patients treated with
cisplatin-based chemotherapy were enrolled. Ten healthy
volunteers age and sex matched were recruited in the control
arm. The encoding of the samples was performed by the staffs
of the Oncology Unit of the Sant’Andrea Hospital. In accor-
dance with the guidelines approved by the management of
Sant’Andrea Hospital for routine care purposes, 7.5mL of
peripheral blood was collected from each patient, for CTC
evaluation before chemotherapy (baseline), at the time of first
posttreatment CT scans (T1), and for still living patients, at
the time of second posttreatment CT scans (T2). EDTA
blood samples were delivered directly to the Cellular Diag-
nostics Unit laboratory and immediately processed to isolate
the PBMC using density gradient centrifugation. CTCs were
isolated by immunomagnetic negative depletion and detected
with RT-PCR as described above.
2.2.2. Statistical Methods. All the correlation measures in the
recovery experiments and calculations of RT-PCR efficiency
were evaluated by the Pearson test (r2) and by linear analysis
of regression curve. To compare the analytic methods, the
Bland & Altman plot was performed; the limits of agreement
for interchangeability of the methods are defined as the mean
difference plus and minus 1.96 times the standard deviation
of the differences. Analysis of the overall survival and time-
to-progression disease was conducted in accordance with
the method of Kaplan-Meier with log-rank test. For CTC-
positive versus CTC-negative patients, the median time to
progression disease was defined as the length of time
from the T0 analysis (baseline) and the consequent begin-
ning of chemotherapy, until disease progression. Probability
values <0.05 were considered to be statistically significant.
3. Results
3.1. Assessment of the Induction of TGF-β1-Mediated
EMT in A549 Cells. For the analysis of early EMT-like
phenotypic change activation in the TGF-β1-mediated
EMT processes in A549 cells, we assessed the morphology,
immunophenotype, and gene expression characteristics of
treated versus untreated cells.
Table 1: Primers used for target and housekeeping genes.
GAPDH For 5′-CATCAGCAATGCCTCCTGCAC-3′
GAPDH Rev 5′-GTCATGAGTCCTTCCACGATACCAA-3′
CEA For 5′-AGGACAGAGCAGACAGCAGAG-3′
CEA Rev 5′-GGTTCCAGAAGGTTAGAAGTGAGG-3′
CK19 For 5′-CCTGACACCATTCCTCCCTTC-3′
CK19 Rev 5′-CCGACGACTGGCGATAGC-3′
ZEB1 For 5′-GGGAGGAGCAGTGAAAGAGA-3′
ZEB1 Rev 5′-TTTCTTGCCCTTCCTTTCTG-3′
ZEB2 For 5′-AAGCCAGGGACAGATCAGC-3′
ZEB2 Rev 5′-CCACACT CTGTGCATTTGAACT-3′
Snail1 For 5′-GCTGCAGGACTCTAATCCAGA-3′
Snail1 Rev 5′-ATCTCCGGAGGTGGGATG-3′
Snail2 For 5′-TGGTTGCTTCAAGGACACAT-3′
Snail2 Rev 5′-GCAAATGCTCTGTTGCAGTG-3′
Twist1 For 5′-AGCTACGCCTTCTGGTCT-3′
Twist1 Rev 5′-CCTTCTCTGGAAACAATGACATC-3′
Twist2 For 5′-CATGTCCGCCTCCCACTA-3′
Twist2 Rev 5′-GCATCATTCAGAATCTCCTCCT-3′
Vimentin For 5′-AATCCAAGTTTGCTGACCTCTCTG-3′
Vimentin Rev 5′-TCATTGGTTCCTTTAAGGGCATCC-3′
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With a phase-contrast microscopy analysis, untreated
A549 showed a typical epithelial morphology with clear cell-
cell adhesion, while A549 TGF-β1-treated cells presented a
reduction of intercellular contacts and a spindle-like mor-
phology, suggestive of EMT. At the immunofluorescence
assay, A549 TGF-β1-treated cells also showed a vimentin
expression close to 100% and a severe reduction of epithelial
adhesion molecule expression EpCAM that, in contrast, is
widely expressed in untreated A549 (Figure 2(a)).
The induction of EMT TGF-β1-dependent on A549 cells
was confirmed by RT-PCR analysis of mRNA expression
levels for vimentin and for transcription factors Snail, Twist,
and ZEB. The cycle threshold (Ct) comparison applied to cal-
culate target gene expression changes induced by treatment
showed a noticeable increase of the expression of all mesen-
chymal genes analyzed. In the A549-TGF-β1-treated cells,
the mRNA fold increase amounted to over 3600 times for
vimentin, about 17 and 6.5 times, respectively, for ZEB1
and ZEB2, 23 and 72 times for Snail1 and Snail2, and 6 and
3 times for Twist1 and Twist2 with respect to untreated
A549 cells. The mRNA expression for CEA and CK19 was
decreased with respect to the untreated A549 (Figure 2(b)).
3.2. Recovery Experiments of Spiked A549EMT Cells and
Reliability Evaluation of the RT-PCR Assay. Once confirmed,
the induction of TGF-β1-mediated EMT in A549 cells, we
spiked tenfold serial dilutions of A549EMT in whole blood
samples from healthy volunteers and we performed the
recovery experiments as above to test the reliability and line-
arity of our detection method.
To count the spiked A549EMT cells, all dilutions were
analyzed in parallel by qIF and CF assays. The mean recovery
rates at lower dilutions (101 and 102) were of 61± 14% and
80± 17% for qIF and 84± 16% and 56± 32% for CF
(Figure 3(a)). The linearity of both methods was verified by
linear analysis of regression curve (r2: 0.88 and 0.97 for qIF
and CF assays, resp., Figure 3(b)).
The reliability of RT-PCR method was assessed by Bland
& Altman plot. The expression levels of all target genes were
compared to qIF and CF cell counts. The RT-PCR assay was
found consistent and interchangeable with both CTC count
methods (Figure 4(a)). Finally, the linearity of RT-PCR assay
was confirmed by linear regression analysis; a significant cor-
relation between the number of spiked A549EMT and levels of
mRNA expression was found for all target genes, mainly for
the expression of vimentin, Snail2, and Twist1 (Figure 4(b)).
3.3. Detection of CTCs in NSCLC Patients. We evaluated
peripheral blood samples from ten patients with metastatic
NSCLC and ten healthy volunteers. Clinical and histopatho-
logical characteristics of patients are summarized in Table 2.
Performance status (PS) was classified according to the East-
ern Cooperative Oncology Group (ECOG) score. Putative
tumor cells recovered after immunomagnetic depletion of
CD45+ cells were analyzed by RT-PCR. Samples with both
CEA and CK19 and/or one of the EMT-related genes
(vimentin and/or EMT transcription factors) expressed
above the cutoff levels (Figure 4(c)) were considered positive
for CTCs. At baseline (Figure 5), three of ten samples were
positive for CTCs; particularly, a patient (LC6) was found
positive for CTCs with mixed epithelial and mesenchymal
molecular profile, while two patients (LC7 and LC8) were
positive for CTCs with mesenchymal molecular profile. All
the subjects from the control group showed mRNA levels
below the cutoff.
After four cycles of first-line platinum-based chemother-
apy (T1, median time 140 days from baseline), two patients
were excluded from the study (LC1 received treatment at
another centre, and LC7 died at the early steps of the current
study). By this time, the percentage of patients with CTC pos-
itivity showed a strong increase (T1; Figure 5): two patients
showed positivity for CTCs with an epithelial profile (LC4
who was negative at T0 and LC6), two showed positivity for
CTCs with mixed profile (LC3 and LC9), and three showed
positivity for CTCs with mesenchymal profile (LC5, LC8,
and LC10).
3.4. Prognostic Significance of Epithelial and/or Mesenchymal
Phenotype Expression in CTCs. Three patients with CTC
positivity at baseline showed a progression faster than the
counterpart with a negative CTC count (median time to
progression: 190 versus 275 days; P=NS). The positivity
for CTCs expressing mesenchymal phenotype after the first
four cycles of chemotherapy treatment seems to be related
to a more unfavorable prognostic trend: patients who
develop CTCsEMT-positive at the T1 showed a progression
or a faster progression time (median time to progression:
1 day for CTCsEMT-positive versus 90 days for CTCsEMT-
negative patients in T1; P=NS) and showed a notable shorter
overall survival (median time of OS: 148 days for CTCsEMT-
positive versus 350 days for CTCsEMT-negative patients
in T1; P=NS).
3.5. Dynamic Variations in the CTC Molecular Profile:
Clinical Outcomes and Therapeutic Response. Three patients
still alive were treated with taxane-based chemotherapy
and underwent to a third levy during the second posttreat-
ment CT scan (T2) to verify a possible association between
the positivity for CTCsEMT and the therapeutic response or
progression.
The LC3 patient had a stable disease at T2 while previ-
ously positive for CTCs, and he showed a partial reversion
of the molecular profile (a negative expression of vimentin,
Twist1, and ZEB2, which were previously positive at T1). A
partial reversion of CTC mesenchymal phenotype was also
found in the LC8 patient who was also clinically stable at
T2. Instead, the LC5 patient, who had a clinical progression
of disease at T2, besides confirming the positivity for ZEB2
and Twist1 and 2 presented an accentuated tendency toward
the expression of EMTmarkers with a positive status of ZEB1
and Snail1 (Figure 6).
4. Discussion
EMT leads to epithelial cell dedifferentiation and acquisition
of cell motility and invasiveness through the rearrangement
of cell junctions and loss of cell adhesion factors; this
mechanism, which is involved in organogenesis and wound
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Figure 2: Representative micrographs showing the assessment of TGF-β1-mediated EMT in A549 cells. (a) The morphological analysis by
differential interference contrast microscopy of the A549 cells exposed to TGF-β1 shows the acquisition of an elongated morphology with
reduction of intercellular contacts compatible with EMT-like compared to unexposed A549 cells. (b) The immunofluorescence analysis
reveals a dramatic reduction of EpCAM-positive cells (red fluorescence) in A549 cells exposed to TGF-β1 as compared to unexposed
cells which retain the typical bordered staining. Furthermore, the A549 TGF-β1-treated cells showed a strong intracytoplasmic positivity
for vimentin.
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healing, is implicated in the dissemination of neoplastic
cells, and it has also been associated with the aggressiveness
of the tumor and the migration of malignant cells from the
primary mass [2–4]. Despite a recent meta-analysis on the
significance of CTCs in lung cancer patients that has estab-
lished the prognostic value of CTC positivity based on
detection of epithelial markers [32], these standard
methods can easily fail when the partial loss of epithelial
markers due to epithelial-mesenchymal plasticity leads to
an underestimation of the CTCsEMT with hybrid or mesen-
chymal phenotype [16, 18–20, 33].
The usefulness of assessing other tumor markers and/or
the coexpression of different target genes has been clearly
documented [14, 25–27, 34, 35]. Therefore, in a setting of
metastatic NSCLC patients, we tried to optimize a method
of enrichment for CTC detection based on negative immuno-
magnetic selection of CTCs associated with a RT-PCR anal-
ysis for the expression of epithelial (CEA and CK19) and
EMT-related markers such as vimentin and transcription
factors (Snail1 and 2, ZEB1 and 2, and Twist1 and 2).
The choice of EMT-related genes comes from the fact
that ZEB and Snail act directly on E-cadherin gene promoter
sequences inhibiting its expression, while Twist genes act
indirectly because they have a crucial role on maintaining
stem properties of cancer cells through activation of beta
catenin and AKT pathway [36, 37]. Snail genes seem to be
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Figure 3: Recovery experiments of spiked A549EMT cells and linearity assessment of control methods for cell count. (a) qIF and CF cell counts
of spiked A549EMT cells. All dilutions were analyzed in parallel; the mean recovery rates at lower dilutions (101 and 102) were of 61± 14% and
80± 17% for qIF and 84± 16% and 56± 32% for CF. (b) Evaluation of the linearity of qIF and CF cell counts. The linearity of both methods
was verified by linear analysis of regression curve (r2: 0.88 and 0.97 for qIF and CF assays, resp.).
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Figure 4: Reliability assessment of the RT-PCR assay. (a) Comparison between RT-PCR assay and control methods for cell counts. The
reliability of RT-PCR method was assessed by Bland & Altman plot. At the different experimental points, the differences between methods
were within mean± 1.96 SD; therefore, the RT-PCR assay was interchangeable with both the qIF and CF assays. (b) Evaluation of the
linearity of RT-PCR assay. A significant correlation between the number of spiked A549EMT cells and levels of mRNA expression was
found for all target genes, mainly for the expression of vimentin (r2: 0.68), Snail2 (r2: 0.72), and Twist1 (r2: 0.69). (r correlation coefficient
for other target genes: Snail1 (r2: 0.68), Twist2 (r2: 0.68), ZEB1 (r2: 0.57), and ZEB2 (r2: 0.37)). (c) ROC curves and cutoff values for EMT-
target genes (VIM: >0.678; sens 83.3, spec 73.6, likelihood 3.17, AUC 0.837, P < 0 01; Twist1: >0.551; sens 100, spec 83.3, likelihood 6.00,
AUC 1.00, P < 0 0001; Twist2: >0.551, sens 100, spec 83.3, likelihood 6.00, AUC 1.00, P < 0 0001; Snail1: >0.718, sens 74.0, spec 83.3,
likelihood 4.44, AUC 0.77, P < 0 05; Snail2: >0.559, sens 96.0, spec 83.3, likelihood 5.76, AUC 0.993, P < 0 0001; ZEB1: >0.765, sens 72.0,
spec 83.3, likelihood 4.32, AUC 0.736, P < 0 05; ZEB2: > 0.88, sens 92.0, spec 83.3, likelihood 5.52, AUC 0.923, P < 0 001).
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directly involved in EMT in many types of cancer by induc-
ing cancer cells to enter in the systemic circulation [38];
ZEB and Twist are involved in EMT, and they induce
stem cell neoplastic properties [39, 40]. In the NSCLC
patients, the overexpression of Snail is associated with
reduced survival [41].
The aim of the study is to show that an alternative CTC
detection approach focused in the recognition and associa-
tion of epithelial and mesenchymal markers directly
involved in EMT can lead to a better recovery of the CTCs.
The feasibility of this method was confirmed by our experi-
ments on A549EMT cell lines by linking spiked A549EMT,
recovered cells, and mRNA expression. After that, we evalu-
ated the same approach on blood samples from our series of
NSCLC patients.
At the time of the enrolment, 30% of the patients were
found to be positive for CTCs, and in two-thirds of cases, this
positivity was related exclusively to the expression of mesen-
chymal target genes. The positivity for CTCs seems to be
increased significantly in T1 achieving a percentage close
to 90%, and in more than half of the patients (62.5%),
there was a positivity in the expression of mesenchymal
markers. Finally, two patients express exclusively mRNA of
a transcription factor related to EMT, without any expression
of vimentin, CEA, and CK19. This strong increase of mesen-
chymal target genes in T1 is probably related to chemother-
apy; it is possible that chemotherapeutic drugs directly
promote EMT [42] or a drug-induced debulking where
highly dividing nonmesenchymal cells die sparing the more
quiescent mesenchymal-like cells [43]. Anyhow, the develop-
ment of CTC positivity after therapy is an unfavorable prog-
nostic factor; in fact, we observed that the positivity for
CTCsEMT during chemotherapy is associated with faster pro-
gression and shorter overall survival.
Our data lack of any statistical ambition, but these results
are only anecdotal and have shown how chemotherapy
response and a stable disease are associated with phenotypic
transition from mesenchymal to epithelial markers (MET),
while no response and disease progression are associated
with expression of markers related to EMT. Nel et al. found
similar results in their study where CTCs were negatively
enriched by hematopoietic cell depletions from blood
samples, and then they were further characterized by multi-
immunofluorescence staining against pan-CK, EpCAM, N-
cadherin, stem cell marker CD133, CD45, and nuclear
counterstain DAPI: the presence of mesenchymal N-
cadherin-positive cells was associated to shortened PFS (5
versus 8 months, P=0.03, HR=2.63) [44]. In that study,
however, they took 20mL of blood from 43 patients with
NSCLC at various stages of disease (56% stage IV) using,
after the negative selection, immunofluorescence, a method
with a poor sensitivity. In another study in NSCLC patients,
CTCs were highlighted by CK7 mRNA expression mea-
sured by RT-PCR; there was not a significant association
between CK7 mRNA levels and the response to chemother-
apy or the survival [45]. Based on our data, we think this
contrasting result is due to the use of only one epithelial
marker and so it emphasizes how the expression of mesen-
chymal markers in combination with epithelial ones can
significantly improve the CTCs detection. These conclu-
sions are consistent with the current literature, where the
emergence of EMT may explain the onset of resistance to
chemotherapeutic approaches and thus represent a particu-
larly valuable target to be considered in clinical practice to
predict worse prognoses [46–48]. In a meta-analysis asses-
sing the predictive and prognostic significance of CTCs in
lung cancer patients treated with chemotherapy, the authors
found that patients converted from CTC-negative to CTC-
positive and patients persistently CTC-positive had a worse
disease control rate compared to those converted from
CTC-positive to CTC-negative or to patients persistently
negative [49].
5. Conclusions
At the current time, no procedures are considered “the gold
standard” for CTC evaluation as a prognostic or predictive
marker. It is because many studies recruited too few patients,
the methods used are varied, and the findings are contradic-
tory or inconclusive [50]. Limits of the extensive use of CTC
assay in clinical practice are various. There is not a consensus
about requirements necessary and sufficient to define an
event as CTCs in the blood. The available technologies for
CTC detection are often very expensive and require specific
equipment and qualified technical personnel. In addition,
the EpCAM-dependent strategies lack of sensitivity, so the
Table 2: Clinical and histopathological characteristics of ten non-
small cell lung cancer patients.
Factors Subgroup N %
Median age at baseline 69.9 y (45–70)
Sex
Male 6 60
Female 4 40
Smoker
Yes 5 50
No 2 20
Unknown 3 30
ECOG PS
0-1 10 100
2 0 0
Histopathology
Adenocarcinoma 9 90
Squamous cell 1 10
Mutational status
EGFR mutation 0 0
ALK translocation 1 10
ROS1 translocation 1 10
None 8 80
Metastasis location
Bone 1 10
Liver 1 10
Contralateral lung 4 40
Adrenal gland 1 10
Brain 3 30
Chemotherapy
CDDP-pemetrexed 7 70
CDDP-gemcitabine 2 20
CDDP-taxotere 1 10
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more aggressive and undifferentiated CTC EMT will be
underestimated and cannot be correctly quantified.
Our study covers a hot topic in the field of transla-
tional biology; in fact, it proposes an inexpensive, simple,
and reliable method to highlight the CTCs with EMT phe-
notype. The RT-PCR method does not require highly spe-
cialized laboratories, and the costs are not the “stumbling
block” [51]. Moreover, although the results are based on
a small number of patients, it highlighted that EMT may
occur in CTCs, CTC count should not be just based on
EpCAM detection, and EMT-related gene expression by
CTCs could have a significance in terms of prognosis and
response to chemotherapy.
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